China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd.

Related Keywords

China , Nanjing , Jiangsu , Chinese , , Wuxi Apptec Co , Juventas Cell Therapy Ltd , Pharmaceuticals Inc , Juno Therapeutics Inc , Legend Biotech Corp , Johnson , Nanjing Legend Biotech Corp , Juno Therapeutics , Wuxi Apptec , Juventas Cell Therapy , Bioworld , Johnson Amp , Nanjing Legend Biotech Co , Wuxi Apptec Co Ltd , Casi Pharmaceuticals Inc , Asia Pacific , Car T , Analysis And Data Insight , Deals Andm Amp A , Cancer , Nmpa ,